- $57.87m
- $34.92m
- $10.99m
Annual balance sheet for Opus Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.4 | 24.8 | 42.7 | 50.5 | 30.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 4.85 | 2.33 | 5.77 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.7 | 26.1 | 49 | 53.9 | 36.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.014 | 0.01 | 0.006 | 0 | 0.252 |
| Total Assets | 17.7 | 26.1 | 49 | 53.9 | 36.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.19 | 3.85 | 2.75 | 4.04 | 11.3 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 31.1 | 3.85 | 2.75 | 4.04 | 11.3 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -13.5 | 22.2 | 46.2 | 49.9 | 25.6 |
| Total Liabilities & Shareholders' Equity | 17.7 | 26.1 | 49 | 53.9 | 36.9 |
| Total Common Shares Outstanding |